STAT+: Up and down the ladder: The latest comings and goings

STAT PlusPharmalot Up and down the ladder: The latest comings and goings Ailux hired Maria Belvisi as chief scientific officer, and more pick ups and promotions Manage alerts for this article Email this article Share this article By Ed SilvermanMay 1, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week. This time around, we note that Ailux hired Maria Belvisi as chief scientific officer. Previously, she worked at AstraZeneca, where she was senior vice president, research and development, respiratory & immunology, biopharmaceuticals R&D.Advertisement But all work and no play can make for a dull chief scientific officer. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. STAT+ Newsletter Pharmalot columnist Ed Silverman rounds up the most important news of the day in the global drug industry Recommended Pharmalot May 1, 2026 STAT Plus: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more Pharmalot April 30, 2026 STAT Plus: FDA wants to exclude weight loss drugs from a compounding list Advertisement Pharmalot April 30, 2026 STAT Plus: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more Pharmalot April 29, 2026 STAT Plus: Supreme Court justices appear to signal ‘skinny labeling’ can survive Pharmalot April 29, 2026 STAT Plus: Pharmalittle: We’re reading about the FDA speeding up trials, a Supreme Court hearing on ‘skinny labels,’ and more Subscriber Picks